Literature DB >> 29028632

Procalcitonin as a diagnostic and prognostic marker in diabetic foot infection. A current literature review.

Dimitrios Velissaris1, Nikolaos-Dimitrios Pantzaris1, Christina Platanaki1, Nikolina Antonopoulou1, Charalampos Gogos1.   

Abstract

Diabetic foot ulcers (DFUs) are a very common cause of mortality and morbidity. The distinction between infected and non-infected DFU remains a very challenging task for clinicians in everyday practice. Even when infection is documented, the spectrum of diabetic foot infection is wide, ranging from cellulitis and soft tissue infection to osteomyelitis. Procalcitonin (PCT), a well-established sepsis biomarker, has been used in the diagnosis of several infections including osteomyelitis in patients with diabetes mellitus. This review gathers and presents all the relevant data, up until now, regarding the use of PCT as an assessment tool in diabetic patients with foot infection. Current evidence suggests that PCT levels could aid clinicians in distinguishing infected from non-infected DFUs as well as in the distinction between soft tissue infection and bone involvement, but further and larger studies are warranted to confirm these findings.

Entities:  

Keywords:  diabetes mellitus; diabetic foot; diabetic foot infection; diabetic foot osteomyelitis; diabetic foot ulcer; inflammatory biomarkers; osteomyelitis; procalcitonin

Mesh:

Substances:

Year:  2018        PMID: 29028632     DOI: 10.1515/rjim-2017-0039

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  3 in total

1.  Antimicrobial Photodynamic Therapy Involving a Novel Photosensitizer Combined With an Antibiotic in the Treatment of Rabbit Tibial Osteomyelitis Caused by Drug-Resistant Bacteria.

Authors:  Xiujuan Yin; Ziyuan Fang; Yan Fang; Lin Zhu; Jinwen Pang; Tianjun Liu; Zhanjuan Zhao; Jianxi Zhao
Journal:  Front Microbiol       Date:  2022-04-22       Impact factor: 6.064

2.  Influence of micro- and macro-vascular disease and Tumor Necrosis Factor Receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes.

Authors:  Fabrice Schneider; Pierre-Jean Saulnier; Elise Gand; Mathieu Desvergnes; Nicolas Lefort; Eric Thorin; Nathalie Thorin-Trescases; Kamel Mohammedi; Stéphanie Ragot; Jean-Baptiste Ricco; Samy Hadjadj
Journal:  Cardiovasc Diabetol       Date:  2018-06-08       Impact factor: 9.951

3.  Clinical Study of MEBO Combined with Jinhuang Powder for Diabetic Foot with Infection.

Authors:  Hong-Bo Zhan; Qing-Qing Sun; Lei Yan; Jia Cai
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.